Advancing management of bradycardia one beat at a time
MAT-2403640 v2.0 | Item approved for U.S. use only. ©2025 Abbott. All Rights Reserved.
AVEIR VR Ventricular Leadless Pacemaker (LP) is the next evolution in leadless technology that is ideal for patients requiring single chamber pacing for bradycardia or other rhythm disorders.1 AVEIR VR LP has been designed for:
The AVEIR VR LP's predecessor has an overall long-term retrieval success rate of 88% with helix fixation through 9 years of retrieval experience. Limited data is available for AVEIR VR LP.
The AVEIR VR LP's predecessor has an overall long-term retrieval success rate of 92.5% for implants ≥ 5 years.
Increased projected battery longevity over current available leadless pacemakers4,5* opens the door to more patients.
The average battery longevity among Leadless II phase 2 IDE patients at 1 year follow-up is estimated to be 17.6 years6
48% of the study patients have an estimated battery longevity of over 20 years.6
Patient therapy can be tailored by implanting a ventricular device alone, or both an atrial and ventricular device combined for dual chamber support. The option to upgrade over time allows you to meet your patient’s needs today and adapt to common disease progression later.
Treat rare intermittent heart block today.
Add an atrial device for sick sinus syndrome later.
Enable i2i™ communication.
Activate dual chamber pacing therapy DDD(R) via i2i communication.
REFERENCES
* Battery longevity estimates based on projections derived from published technical specifications and the ISO standard settings
**For additional information about specific MR Conditional, including warnings, precautions, adverse conditions to MRI scanning and potential adverse events, please refer to the MRI-Ready Leadless Systems Manual at medical.abbott/manuals or check our MRI-Ready resources at cardiovascular.abbott/mriready
MAT-2115643 v12.0 | Item is approved for U.S. use only
Stay Connected